Objective-In endothelial cells, cyclooxygenase-1 (COX-1) and COX-2 both contribute to prostacyclin production. Recent findings suggest that COX-2 contributes significantly to systemic prostacyclin synthesis in humans; whether COX-2 inhibition is related to an increased cardiovascular risk is undergoing debate. HDLs have been shown to increase prostacyclin synthesis, thus in the present study we investigated the molecular mechanisms involved in this effect in endothelial cells. Methods and Results-HDL 3 (30 g/mL) induced COX-2 expression in a time-and dose-dependent manner. COX-2 was found mainly in the perinuclear area where it co-localizes with PGI synthase. Transient transfection experiments showed that CRE is required for HDL-induced COX-2 transcription, and we demonstrated that p38 MAPK activation by HDL 3 is involved in COX-2 mRNA transcription and stabilization. As a consequence of COX-2-induction by HDL 3 prostacyclin production increased, incubation with a COX-2 selective inhibitor blocked this effect. Moreover, HDL 3 increased caveolin-1 phosphorylation, thus promoting PGI-synthase shuttling from the membrane to the perinuclear area. Conclusion-We conclude that in endothelial cells, HDL modulates COX-2/PGI-S activity via both p38 MAPK-dependent COX-2 mRNA stability and transcription and both caveolin-1-dependent PGI-synthase shuttling and COX-2 coupling. The understanding of these mechanisms may provide new insights into the antiatherogenic role of HDL. (Arterioscler Thromb Vasc Biol. 2004;24:871-877.)
H igh-density lipoprotein (HDL) protects from atherosclerotic vascular disease. 1 Beyond reverse cholesterol transport, HDL particles posses several anti-atherosclerotic effects, 2 including the induction of prostacyclin (PGI 2 ), a strong vasorelaxant 3 that acts also as an inhibitor of platelet and leukocyte activation. 4 The stimulatory effect on PGI 2 depends mainly on the supply by HDL of endothelial cells with arachidonic acid. 3 The rate-limiting step in the conversion of the arachidonic acid to eicosanoids is the activity of cyclooxygenase (COX). 4 Two major forms of COX, COX-1 and COX-2, have been identified. 5 Although COX-1 is constitutively expressed in most cell types, COX-2 is induced by various growth factors and cytokines. 6, 7 Recent findings suggest that COX-2 contributes significantly for PGI 2 synthesis in endothelial cells, 8, 9 whereas COX-1 is mainly involved in TXA 2 synthesis by platelets. 8, 9 Whether COX-2 inhibition is related to an increase of cardiovascular risk is uncertain. 10 HDL induces COX-2 expression in rabbit smooth muscle cells 11 and cooperates with TNF-alpha to elicit this effect, 12 the molecular mechanisms involved, however, are unclear. COX-2 expression is modulated by growth factors and cytokines via mitogen-activated protein kinase (MAPKs) cascade. 13, 14 Once activated, the MAPKs may modulate the activity of several transcription factors such as CREB, NFAT, AP-1, and NF-KB, [15] [16] [17] which are involved in COX-2 expression. 18 -21 In the present study, we investigated the molecular mechanisms involved in the effect of HDL 3 on COX-2 expression and eicosanoid production in cultured human endothelial cells.
Methods HDL 3 (density 1.125 to 1.21 g/mL) was isolated from human plasma and protein content was determined as described. 22 HDL 3 was used within 6 hours from isolation. No LPS contamination was detected as assessed by the endotoxin kit (Sigma, Italy).
HUVECs were isolated and cultured as described. 23 In all experiments, cells were preincubated with serum-free medium for 6 hours, [22] [23] [24] then HDL 3 was added.
The antibodies to phospho-p38 MAPK, phospho-p44/42 MAPK, phospho-IkB-alpha, phospho-CREB, and phospho-caveolin-1 were from New England Biolabs (Germany). COX-1, COX-2, and PGI and PGE synthase (PGIS, mPGES-1) monoclonal antibodies were from Cayman (USA). ␤-Actin antibody was from Sigma. Secondary antibodies were from Biorad (Italy). Western blotting analysis was performed as described; 23 all antibodies were diluted 1:1000, except ␤-actin (1:10000).
The MEK inhibitor, U0126 (New England Biolabs), and the p38 MAPK inhibitor SB203580 (Sigma) were used at a final concentration of 10 mol/L and 1 mol/L, respectively. Indomethacin heptyl ester (Cayman), a selective COX-2 inhibitor, 25 was used at 0.1 mol/L.
Immunocytochemistry
Cells were cultured on coverslips in 24-well plates. Fixed cells 23 were incubated with a monoclonal antibody for COX-1 or COX-2 (1:50) overnight at 4°C, followed by incubation with anti-mouse IgG FITC-conjugated (1:100, RD, Italy) for 30 minutes, then propidium iodide (2,5 g/mL) was added for 30 minutes. For the studies of COX-2 co-localization with PGI-S, mPGES-1 and phosphocaveolin-1 fixed cells were incubated overnight with the antibody, followed by incubation with anti IgG FITC-conjugated (30 minutes), anti-COX-2 phycoerythrin-labeled for 1 hour, and TOPRO 3 (Molecular Probes) (1:500) for 15 minutes. The coverslips were analyzed with a confocal microscope (Nikon Eclipse TE 2000-S; Radiance 2100 Biorad) at 600ϫ magnifications. Sixty sections were captured (0.01 m each) and a three-dimensional reconstruction was obtained using the software Image ProPlace 4.5 (Media Cybernetics, USA).
Real-Time Quantitative Reverse-Transcriptase Polymerase Chain Reaction
Total RNA was extracted and underwent reverse transcription as described. 22, 24 Three L of cDNA were amplified by real-time quantitative polymerase chain reaction (PCR) with 1ϫ Syber green universal PCR mastermix (Biorad). The specificity of the Syber green fluorescence was tested by plotting fluorescence as a function of temperature to generate a melting curve of the amplicon. The melting peaks of the amplicons were as expected (not shown). The primers used, the amplicon size, and the melting temperature are indicated in online Table I (available online at http://atvb.ahajournals.org). Each sample was analyzed in duplicate using the IQ TM -Cycler (Biorad). The PCR amplification was related to a standard curve ranging from 10 Ϫ11 M to 10 Ϫ14 M.
Transcription Assay
The construction of various reporter vectors for the human COX-2 gene has been described previously. 20, 21 Transfection experiments were first performed using HUVECs and EAhy 926 cells; however, the efficiencies reached were very low, with a high degree of cytotoxicity (data not shown). Because human COX-2 promoter regulation is similar in a wide number of cell types, 26 -28 we performed transfection experiments in CHO cells, a cell line widely used for studies involving the effects of HDL in vitro. 29, 30 CHO cells were transiently transfected with COX-2 (nucleotide Ϫ327/ϩ59), the NF-kB mutated site (KBM), or the CRE mutated site (CRM) luciferase reporter vectors using lipofectamine (Invitrogen, Italy) according to the manufacturer instructions. Luciferase activity was determined and normalized for the cellular protein concentration. 21
Detection of Prostaglandin Release by Competitive Enzyme Immunoassay
Competitive enzyme immunoassay kits for 6-keto PGF 1 ␣, TXB 2, and PGE 2 were from Cayman. HUVECs were exposed to HDL 3 (30 g/mL) for 6 hours, washed twice with PBS, and then incubated for 30 minutes with exogenous AA (10 mol/L); 50 L for each sample were processed for prostaglandin release according to the manufacturer instructions.
Statistical Analysis
Statistical analysis was performed by ANOVA with the use of Statsoft Statistica Package.
Results

HDL 3 Induces COX-2 Expression in HUVECs
COX-2 protein was expressed at low levels in unstimulated cells and was strongly induced 2 hours after exposure to HDL 3 (30 g/mL). In preliminary experiments, this concentration maximally induced COX-2 expression and no further increase was observed up to 600 g/mL of HDL 3 . The induction was maximal after 4 hours and begun to decrease after 8 hours ( Figure 1a ). In unstimulated cells, COX-2 expression remained low at all time points (data not shown). Under the same experimental conditions, HDL 3 did not affect COX-1 expression ( Figure 1a ). These findings were confirmed by immunocytochemistry. COX-2 expression increased after 4 hours in cells incubated with HDL 3 without changes of COX-1 expression ( Figure 1b ). On threedimensional reconstruction, COX-2 localized in the perinuclear area and in the cytoplasm 31 (Figure 1c ).
Effects of HDL 3 on Intracellular Kinase Pathways and on COX-2 Promoter Activity
HDL 3 activated ERK1/2 and p38 MAPK, with a the peak of phosphorylation reached after 5 to 10 minutes of incubation ( Figure 2 ). Several transcription factors are activated through MAPK-dependent pathways. [17] [18] [19] HDL 3 activated CREB, with a peak of activity at 10 to 20 minutes ( Figure 2 ), in agreement with the observation that both ERK1/2 and p38 MAPK activate CREB via p90RSK or via MSK-1, respectively. Ik-B alpha phosphorylation results in the release and nuclear translocation of active NF-kB. 17 Under our experimental conditions, a basal level of phosphorylation of Ik-B alpha was present, and only a minimal effect on phosphorylation was observed after 5 and 10 minutes of incubation with HDL 3 (Figure 2 ). The human COX-2 promoter region (Ϫ327/ ϩ59) contains the NF-kB, the NF-IL6, and the CRE sites. 20, 21 Transient transfection assay showed that HDL 3 induced promoter activity by 2.96Ϯ0.03-fold, whereas LPS (1 g/ mL), a positive control, induced promoter activity by 4.24Ϯ0.02-fold (PϽ0.01 for both versus control) ( Figure 3 ). The promoter activity of the plasmid carrying the mutation at the NF-kB site was 1.87Ϯ0.12 fold in HDL 3 incubated cells (PϽ0,01) and 0.93Ϯ0.09 fold in LPS-treated cells, whereas that of the mutant carrying the mutation at the CRE site was 1.15Ϯ0.03-fold in HDL 3 -treated cells and 1.26Ϯ0.16-fold in LPS treated cells ( Figure 3 ; PϭNS versus control).
Involvement of p38-MAPK in HDL 3 -Induced COX-2 Protein and mRNA Expression and Stabilization
Cells were preincubated with the MEK1 inhibitor U 0126 (25 mol/L) or the p38 MAPK inhibitor SB 203580 (1 mol/L) for 1 hour. HDL 3 (30 g/mL) were added for 2 and 4 hours to evaluate COX-2 mRNA and protein expression. U0126 did not affect HDL 3 -induced COX-2 expression. SB203580 strongly inhibited HDL 3 -mediated COX-2 mRNA and protein expression ( Figure 4 ). Because p38 MAPK stabilizes COX-2 mRNA, 32 we investigated whether HDL 3 possesses this effect. To asses the stability of COX-2 mRNA in HUVEC, actinomycin D (2 g/mL) was added to cells after 2 hours of HDL 3 incubation and COX-2 mRNA levels were measured up to 60 minutes (Figure 4 ). Simultaneous addition of SB203580 (1 mol/L) and actinomycin D to the cells after a 2-hour stimulation with HDL 3 resulted in a more rapid decrease in COX-2 mRNA levels, suggesting mRNA stabilizing effect by p38 MAPK activity.
Effects of HDL 3 on Eicosanoid Production
The effects of HDL 3 on eicosanoids production were assessed in HUVECs exposed to 30 g/mL of lipoproteins for 6 hours, followed by 30 minutes of incubation with exogenous AA (10 mol/L). 11 In control cells, the production of 6-keto PGF 1 ␣ (PGI 2 main metabolite) was 73.14Ϯ6.79 pg/mg of cellular protein. Incubation of endothelial cells with HDL 3 increased 6-keto PGF 1 ␣ production to 113.38Ϯ2.54 pg/mg of cellular protein (PϽ0,01) (Table II , available online at http://atvb.ahajournals.org). In the presence of 0.1 mol/L indomethacin eptyl ester, a selective COX-2 inhibitor, 25 HDL 3 -induced 6-keto PGF 1 ␣ production was reduced to 77.95Ϯ10.19 pg/mg of cellular protein and PGE 2 resulted in 74.10Ϯ3.45 pg/mg of cellular protein and was not affected by HDL 3 incubation. 
Effects of HDL 3 on PGI Synthase Expression and Cellular Localization
As HDL 3 induces COX-2 expression and increases PGI 2 release, we investigated whether HDL 3 can affect PGI-S or mPGES-1 expression. HDL incubation did not change PGI-S or mPGES-1 expression (1.10Ϯ0.2-fold and 1.07Ϯ0.5-fold versus control cells, respectively) ( Figure  5a ). Furthermore, in HDL-treated cells, PGI-S co-localized with COX-2 while mPGES-1 showed a different subcellular distribution (Figure 5b ).
PGI-S resides in caveolae in resting cells. 33 Caveolin-1 is the main protein of caveolae, and when phosphorylated 34 it moves into the cytoplasm, 34, 35 shuttling PGI-S in the perinuclear area where it couples to COX-2, 35 thus increasing prostacyclin synthesis. We investigated, therefore, whether HDL can influence caveolin-1 phosphorylation and shuttling in the perinuclear space. After 4 hours of incubation, HDL increased caveolin-1 phosphorylation (Figure 6a ), mainly in the area surrounding the nucleus (Figure 6b ). Moreover, a three-dimensional reconstruction shows that phosphorylated caveolin-1 localizes near COX-2 in the perinuclear area of HDL-treated cells (Figure 6c) , where PGI-S is also located (Figure 6d ).
Discussion
The major finding of this study is that HDL 3 induces COX-2 expression and PGI 2 release in human endothelial cells via p38 MAPK activation. The activation of this signaling pathway promotes COX-2 mRNA transcription and stabilization.
On incubation of cells with HDL 3 , COX-2 protein localized mainly in the perinuclear area, in agreement with previous findings showing that COX-2 accumulation near the nuclear envelope and in the cytoplasm is required for the increase in COX-2-mediated prostanoid synthesis in vascular endothelial cells. 35, 36 This effect is specific for COX-2; in fact, COX-1 was mainly localized in the cytoplasm and was not modulated by HDL 3 ; moreover, PGI 2 synthesis was downregulated by a specific COX-2 inhibitor.
The molecular mechanisms by which HDL 3 induces COX-2 are unknown. Here we show that HDL 3 activates 2 of the major kinases pathways involved in COX-2 gene transcription: ERK1/2 and p38 MAPK. 13, 14 HDL can activate ERK1/2 via cell surface S1P receptor in astroglial cells. 37 However, the possibility that MAPK activation results from plasma membrane cholesterol depletion cannot be excluded. 38 In support of this hypothesis, Smith et al 39 showed that increasing concentration of LDL or free cholesterol decreases COX-2 expression and PGI 2 synthesis. As HDL triggers the release of cholesterol from cells, 2 our observation suggests that cellular cholesterol balance plays an important role in determining COX-2 levels. HDL 3 also activates CREB in a time-dependent fashion, CREB binds to CRE, which serves as an anchor for P300 interaction with upstream transactivators and downstream transcription machinery, 40 thus suggesting that CRE plays a relevant role in COX-2 induction by a number of stimuli. 40 Using transient transfection experiments, we demonstrated that mutation in CRE abrogated the luciferase activity induced by HDL 3 , confirming the role of CRE in HDL 3 -induced COX-2 gene transcription.
NF-kB has also been suggested to be involved in determining COX-2 gene transcription. 20, 21 We show that a mutation in the NF-kB response element abrogates luciferase activity induced by LPS, used as a positive control, while it slightly decreases HDL 3 -induced luciferase activity, suggesting a minor role of this pathway in COX-2 induction by HDL 3 . As transcriptional regulation of the COX-2 gene occurs via activation of MAPKs, 13, 14 we investigated whether inhibition of ERK1/2 or p38 MAPK pathway affected HDL 3 -induced COX-2 mRNA and protein expression. We show that the p38 MAPK pathway is responsible for the induction of COX-2 by HDL 3 .
P38 MAPK plays a housekeeping role in maintaining COX-2 mRNA stability 32 via the recognition of the AUUUA motifs present in the 3Ј untranslated region of COX-2. 41 We therefore studied COX-2 mRNA stability in cells stimulated with HDL 3 . Simultaneous addition of actinomycin D and SB203580 to the cells resulted in a more rapid decrease in COX-2 mRNA compared with actinomycin D alone. This represents a new mechanism by which HDL can influence gene expression at a posttranscriptional level and is likely to contribute to the increase of COX-2 protein levels in endothelial cells.
COX-2 has been proposed to exert both an antiatherogenic or a proatherogenic role depending on the eicosanoids produced and the arterial wall cells where it is expressed. 9 Eicosanoids are involved in a variety of physiological pro- Figure 5 . Effects of HDL 3 on PGI-S and PGE-S mRNA expression and cellular localization. a, HUVECs were incubated for 2 hours with HDL 3 (30 g/mL) and COX-2 mRNA levels were measured using quantitative real-time PCR. Data are meanϮSD of 4 separate experiments. b, cellular localization of COX-2 and PGI-S or PGE-S. The green signal is for PGI-S or PGE-S, the red signal is for COX-2, and the blue signal is the staining for the nucleus. The results are representative of 4 experiments. Figure 6 . Effects of HDL 3 on caveolin-1 phosphorylation and cellular localization. a, HUVECs were incubated for 4 hours with HDL 3 (30 g/mL) and phospho-caveolin-1 levels were determined by Western blotting. b, cellular localization of phosphocaveolin-1. The green signal is for phospho-caveolin-1, the blue is staining for the nucleus. c, Cellular localization of phosphocaveolin-1 and COX-2 (transversal projection). The green signal is for phospho-caveolin-1, the red signal is for COX-2, and the blue signal is the nucleus. d, Cellular localization of phosphocaveolin-1 and PGI-S (transversal projection). The green signal is for phospho-caveolin-1, the red signal is for PGI-S, and the blue signal is the nucleus. The results are representative of 4 experiments.
cesses in atherosclerosis and thrombosis, including leukocyte-endothelial cell adhesion, vasorelaxation, and platelet aggregation. 9 The dominant prostaglandin produced by endothelial cells is PGI 2 . 4 PGI 2 is believed to play a protective role in atherothrombosis. 4 COX-2 contributes significantly to systemic PGI 2 synthesis in humans; 42 therefore, it is possible that COX-2 induced in endothelial cells at lesion-protected areas catalyzes the formation of the anti-atherogenic molecule prostacyclin. This may be the case in the presence of HDL 3 that increases PGI 2 release mediated by AA in endothelial cells. This effect is dependent mainly on COX-2 as indomethacin eptyl ester, a specific COX-2 inhibitor, abolished PGI 2 release induced by HDL 3 . This observation may also be relevant to the recent observation that COX-2 inhibitors may increase CHD risk. 10 In vitro 30 g/mL of HDL 3 induces maximally COX-2 expression, and no further increase is observed up to 600 g/mL (a physiological concentration that constantly bathes arteries in vivo), thus suggesting that low concentrations of HDL are enough to support COX-2 expression, and higher levels may only provide the substrate. Alternatively, the in vitro conditions allow for a better interaction of HDL with cultured endothelial cells as compared with in vivo settings, in which proteoglycans may trap lipoproteins and reduce their availability for interactions with the endothelial cells. The observation that COX-2 induced by HDL 3 does not increase PGE 2 , a proatherogenic eicosanoid, synthesized mainly via COX-2, 12 confirms that COX-2 expression in the arterial wall could play both a proatherogenic or antiatherogenic role, but it is the final eicosanoid produced that is responsible for its proatherogenic or anti-atherogenic properties.
Moreover, HDL 3 -induced COX-2 protein co-localizes with PGI-S in endothelial cells, thus suggesting that in this model, once induced, COX-2 can drive prostacyclin synthesis. PGI-S is associated with caveolae 33 and is activated when shuttled from the plasma membrane in the perinuclear area; 35 moreover, disruption of caveolae organization downregulates prostacyclin production and impairs angiogenesis. 43, 44 Here we demonstrate that HDL 3 induces caveolin-1 phosphorylation, which shuttles with PGI-S from the plasma membrane to the perinuclear area where it co-localizes with COX-2. Furthermore, the possibility that the abundant increase in COX-2 observed can be related to an increase of prostanoids synthesis other than prostacyclin cannot be excluded.
Also, endothelial nitric oxide synthase, the enzyme responsible for nitric oxide synthesis in the endothelium, localizes in the caveolae. 33, 35 Nitric oxide is responsible for several beneficial effects of HDL on endothelial cells, 45 such as helping to maintain endothelial integrity, facilitating vascular relaxation, inhibiting cell adhesion to vascular endothelium, decreasing radical oxygen production, and inhibiting apoptosis. 45 Even if we have not addressed the role of HDL in modulating endothelial nitric oxide synthase shuttling through caveolin-1 phosphorylation, it is conceivable that some of the effects of HDL are mediated via this pathway 46 In summary, our data suggest that in human endothelial cells, HDL can modulate COX-2 expression via p38 MAPKdependent COX-2 mRNA transcription and stabilization.
Moreover, the HDL-dependent caveolin-1 phosphorylation favors PGI-S shuttling and COX-2 coupling. These data add further insights into the molecular mechanisms involved in the anti-atherogenic activity of HDL.
